This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Globus Medical (GMED) Q2 Earnings Beat Estimates, Margins Dip
by Zacks Equity Research
According to Globus Medical (GMED), the increase in R&D expenses is largely focused on Spine and Enabling Technologies.
ResMed's (RMD) Q4 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
ResMed (RMD) records a robust sales performance in fiscal Q4 backed by the ongoing combined availability of cloud-connected AirSense 10 and AirSense 11 sleep devices.
Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View
by Zacks Equity Research
Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.
Stryker (SYK) Q2 Earnings Beat Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurts sales growth and rising costs affect margins.
Inari Medical (NARI) Q2 Earnings Top, Revenues Rise Y/Y
by Zacks Equity Research
Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.
Cigna (CI) Q2 Earnings Beat on Strong U.S. Commercial Unit
by Zacks Equity Research
Cigna's (CI) Q2 results reflect solid premium rate hikes and a growing membership base across its U.S. Commercial and Medicare Advantage businesses.
PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View
by Zacks Equity Research
PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.
Surmodics (SRDX) Q3 Earnings Top Estimates, FY23 View Up
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal third quarter top line on the back of robust Medical Device revenues.
BD (BDX) Q3 Earnings Surpass Estimates, Margins Contract
by Zacks Equity Research
BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal third quarter.
Envista (NVST) Q2 Earnings Top Estimates, Margins Expands
by Zacks Equity Research
Consistent growth in the Specialty Products & Technologies segment and a return to growth in the Equipment & Consumables segment drive Envista's (NVST) Q2 revenues.
Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
STERIS (STE) Q1 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Barring Life Sciences and Dental, rest of STERIS (STE) operating segments report organic revenue growth in fiscal Q1.
McKesson (MCK) Q1 Earnings Beat Estimates, U.S. Sales Strong
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2024 results benefit from growth in the United States. Divestment hurts the International segment.
Fresenius Medical (FMS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Fresenius Medical's (FMS) second-quarter revenues benefit from strong performance across all segments. Inflationary pressure continues to improve, benefiting operating income.
DENTSPLY SIRONA (XRAY) Beats on Q2 Earnings, Ups '23 EPS View
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) Q2 revenues are driven by a rise in demand across key markets, especially in China. Improved pricing and restructuring initiatives boost earnings.
NuVasive (NUVA) Q2 Earnings Meet Estimates, Margins Down
by Zacks Equity Research
NuVasive's (NUVA) second-quarter 2023 results reflect the robust performance of the U.S. Cervical business.
CVS Health (CVS) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Pharmacy drug mix, growth in specialty pharmacy, brand inflation and the acquisitions of Oak Street Health and Signify Health drive CVS Health's (CVS) Q2 revenues.
Penumbra (PEN) Q2 Earnings Top Estimates, Sales View Raised
by Zacks Equity Research
Penumbra's (PEN) U.S. thrombectomy records 50% year-over-year growth, while the international Vascular business sees relatively flat sales in the second quarter.
Nevro (NVRO) Q2 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the second quarter owing to robust domestic and international performances.
Inspire Medical (INSP) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the second quarter.
Exact Sciences (EXAS) Beats on Q2 Earnings, Ups '23 Sales View
by Zacks Equity Research
Strength in Screening revenues and Precision Oncology drive Exact Sciences (EXAS) Q2 performance.
AmerisourceBergen (ABC) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.
Revvity (RVTY) Beats on Q2 Earnings, Lowers '23 EPS View
by Zacks Equity Research
Revvity's (RVTY) second-quarter results reflect the impact of lower COVID-related sales. Both earnings and sales outpace their respective consensus estimate.
Omnicell (OMCL) Q2 Earnings and Revenues Top, '23 View Raised
by Zacks Equity Research
Omnicell's (OMCL) second-quarter 2023 performance reflects strength in advanced services and technical services as well as continued strong execution.
Tenet Healthcare (THC) Q2 Earnings Beat on Solid Hospital Unit
by Zacks Equity Research
Tenet Healthcare's (THC) Q2 results gain on improved adjusted admissions and higher pricing yield. Management expects adjusted EPS of $5.18-$6.03 for this year.